08:12 AM EST, 11/07/2024 (MT Newswires) -- HLS Therapeutics ( HLTRF ) on Thursday reported a narrower third-quarter loss.

The net loss fell to US$4.84 million, or US$0.15 per share, from US$6.9 million, or US$0.21 per share, last year.

Revenue fell to US$14.1 million from US$16 million.

HLS cut its revenue range to US$56.5-57.2 million from the previous US$58.5-59.7 million. The revision is due to year-to-date U.S. Clozaril sales being behind plan and from the negative foreign exchange impact due to the persistent strength of the U.S. dollar.

The company also provided a preliminary outlook for 2025. HLS expects that revenue growth from its promoted product portfolio will be in the high single-digit percentage range.